The International Atomic Energy Agency (IAEA), the World Health Organization (WHO) and Turkmenistan are actively cooperating in the development of cancer services and ensuring the safe and effective use of nuclear medicine in the country's healthcare system.

As part of this cooperation, a preliminary iTRAST mission is being conducted in Turkmenistan, which plays a key role in assessing and strengthening national capacity in the fight against cancer. The iTRAST (Integrated Review of Cancer Control) mission is a comprehensive assessment of a country's capabilities in the prevention, diagnosis, treatment and palliative care of cancer patients.

During the mission, IAEA and WHO experts analyze the existing infrastructure, equipment, qualifications of medical personnel, as well as the regulatory framework governing the use of nuclear technologies in medicine. Special attention is paid to radiation safety and quality control issues.

Based on the results of the mission, analytical data and recommendations for improving cancer services in Turkmenistan will be prepared. These recommendations will be aimed at improving the diagnosis, treatment and care of cancer patients, as well as ensuring high standards of safety and effectiveness in the use of nuclear technologies in medicine.

The iTRAST mission underscores the commitment of the IAEA, WHO and Turkmenistan to joint efforts in the fight against cancer, which is one of the global health challenges. The development of cancer services and the introduction of modern methods of nuclear medicine will improve the quality of medical care, improve patient outcomes and reduce cancer mortality in Turkmenistan.

This initiative is an important step towards achieving the Sustainable Development Goals, which include ensuring a healthy lifestyle and well-being for all people of all ages.